Completed PHASE2 INTERVENTIONAL 2-arm NCT03198585

Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction (Empire HF)

Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction: A Randomized Clinical Trial (Empire HF)

Sponsor: Morten Schou

Conditions Heart Failure With Reduced Ejection Fraction

Interventions Empagliflozin 10 MG Placebo

Updated 8 times since 2017 Last updated: Jan 31, 2020 Started: Jun 29, 2017 Primary completion: Dec 20, 2019 Completion: Jan 17, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Heart Failure With Reduced Ejection Fraction and is currently completed. Morten Schou leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Mar 2020 — Jan 2021 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Nov 2018 — Mar 2020 [monthly]

Recruiting PHASE2

▶ Show 3 earlier versions

Jun 2018 — Nov 2018 [monthly]

Recruiting PHASE2
Apr 2018 — Jun 2018 [monthly]

Recruiting PHASE2
Aug 2017 — Apr 2018 [monthly]

Recruiting PHASE2

First recorded

Jun 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Morten Schou

Data source: Herlev and Gentofte Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Copenhagen, Denmark
• Odense, Denmark